Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0049 Phase 2 Study in Allergic Conjunctivitis
jRCT2031250103Phase 2Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mapracorat in allergic conjunctivitis (AC) (3 arms), sponsored by Senju Pharmaceutical Co., Ltd. Started May 2025; status: completed.
02
Drugs
mapracorat
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031250103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250103.